Please ensure Javascript is enabled for purposes of website accessibility

Exelixis Looking Excellent

By Brian Lawler - Updated Nov 11, 2016 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker reveals promising news on multiple drugs in development.

In the long-awaited American Society of Clinical Oncology abstracts that debuted this week, Rule Breakers pick Exelixis (NASDAQ:EXEL) was relatively well-represented, issuing multiple reports that showed promising progress in several of its anticancer compounds.

Nothing earth-shattering arose regarding Exelixis' data sets on its later-stage multitarget drugs like XL647, nor early-stage compounds such as XL184 and XL765. Still, all of Exelixis' compounds with abstracts at ASCO continued to show at least some activity in fighting cancer, and the phase 2 XL880 stomach cancer drug data particularly stood out.

Considering that Exelixis' lead drugs are only now entering late-stage testing, it's still too early to determine how its compounds will fare against the competition. (That's why I'm not yet directly comparing the company's data to that of rival compounds.) Nonetheless,  Exelixis' ASCO abstracts suggest that the safety and efficacy data for its drugs is definitely good enough to warrant future testing. Then again, GlaxoSmithKline's (NYSE:GSK) decision to pick up XL880 was a good clue that it merited further investigation.

Last week, IMS Health (NYSE:RX) estimated that cancer-drug sales could grow 67% between 2008 and 2012, to $80 billion worldwide. Exelixis' compounds, known as multiple tyrosine kinase inhibitors, attack cancer in a novel way that helps them stand out from the competition. However promising the ASCO data, however, the drugs' real test will come in subsequent trials, as survival data versus other compounds and other more comparable results arrive.

Further early-stage Foolishness:

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$18.40 (1.15%) $0.21
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$44.06 (-0.81%) $0.36
IMS Health Holdings, Inc. Stock Quote
IMS Health Holdings, Inc.
RX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.